Follow-on Biologics Hearing Testimony

This article in Patent Docs discusses how the House Subcommittee on the Courts and Competition Policy heard testimony from seven witnesses, including Momenta Pharmaceuticals General Counsel Bruce Leicher who will be speaking at Business of Biosimilars in September.

Economist Alex Brill mentioned in his testimony that "a properly designed pathway for biogeneric entry will, over time, lead to additional market entrants, lower prices, increased access to drugs and a few billion dollars a year in reduced spending."

Take a look at the full post at Patent Docs to see the rest of Mr. Brill's testimony.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |